FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
June 30, 2000
Study Completion Date
March 31, 2007
Conditions
Extensive Stage Small Cell Lung CancerStage IIIA Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Small Cell Lung CancerStage IIIB Non-small Cell Lung CancerRecurrent Non-small Cell Lung Cancer
Interventions
DRUG
FR901228
Trial Locations (1)
20892
Surgery Branch, Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00020202 - FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter